Abstract
Parkinsons disease (PD) is a neurodegenerative disease with limited pharmacologic therapies. Recent animal studies and one large retrospective study have found NSAIDs to be protective against the development of PD. We decided to test this hypothesis by conducting a nested case-control study using the Saskatchewan drug plan database. Entry to the cohort was defined as the first prescription of an antihypertensive agent between 1980 and 1987 and followed until 1999. Cases were defined as those having received three prescriptions for a dopamine agonist within a year. For each case, ten controls were selected matched to the case by age, calendar time and index date. Conditional logistic regression was used to estimate rate ratios adjusting for gender, previous use of arthritis medication and previous antipsychotic use. Current users of NSAIDs had a slightly higher risk of developing PD (RR= 1.49 [95% CI, 1.11-2.01]). This effect was not seen with past users (RR= 1.18 [95% CI, 0.89-1.59]). Based on the results of our study current users of NSAIDs may be at a slightly higher risk of developing PD. More studies are needed to confirm this finding.
Keywords: NSAIDsd, Parkinson's disease
Current Drug Safety
Title: NSAID Use and the Risk of Parkinsons Disease
Volume: 1 Issue: 3
Author(s): Mahyar Etminan and Samy Suissa
Affiliation:
Keywords: NSAIDsd, Parkinson's disease
Abstract: Parkinsons disease (PD) is a neurodegenerative disease with limited pharmacologic therapies. Recent animal studies and one large retrospective study have found NSAIDs to be protective against the development of PD. We decided to test this hypothesis by conducting a nested case-control study using the Saskatchewan drug plan database. Entry to the cohort was defined as the first prescription of an antihypertensive agent between 1980 and 1987 and followed until 1999. Cases were defined as those having received three prescriptions for a dopamine agonist within a year. For each case, ten controls were selected matched to the case by age, calendar time and index date. Conditional logistic regression was used to estimate rate ratios adjusting for gender, previous use of arthritis medication and previous antipsychotic use. Current users of NSAIDs had a slightly higher risk of developing PD (RR= 1.49 [95% CI, 1.11-2.01]). This effect was not seen with past users (RR= 1.18 [95% CI, 0.89-1.59]). Based on the results of our study current users of NSAIDs may be at a slightly higher risk of developing PD. More studies are needed to confirm this finding.
Export Options
About this article
Cite this article as:
Etminan Mahyar and Suissa Samy, NSAID Use and the Risk of Parkinsons Disease, Current Drug Safety 2006; 1 (3) . https://dx.doi.org/10.2174/157488606777934404
DOI https://dx.doi.org/10.2174/157488606777934404 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Cardiomyocyte Ca<sup>2+</sup> Homeostasis in Heart Failure
Current Pharmaceutical Design A panoramic view of chronic liver diseases and natural remedies reported in Traditional Persian Medicine
Current Pharmaceutical Design The Epidemiology of Sleep Disordered Breathing and Hypertension in Various Populations
Current Hypertension Reviews CD36 as a Multiple-Ligand Signaling Receptor in Atherothrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Imaging Patterns of Cardiovascular Involvement in Mixed Connective Tissue Disease Evaluated by Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) Conference Report (11th International Conference on Neuroprotective Agents, Wendake, Quebec City, Quebec, Canada, Sept 30-Oct 3, 2012)
CNS & Neurological Disorders - Drug Targets Indoleamine 2,3-Dioxygenase in Materno-Fetal Interaction
Current Drug Metabolism Evaluation of Thyroid Hormone Status in Children with Steroid Resistant Nephrotic Syndrome: A North India Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Genomics, Proteomics and Metabolomics Approaches for Predicting Diabetic Nephropathy in Type 2 Diabetes Mellitus Patients
Current Diabetes Reviews An Angiotensin II (Ang II) Type 1 Receptor Blocker, Telmisartan Protects Against Neurological Deficits and Prolongs Survival in Spontaneously Hypertensive Rats Stroke-Prone (SHR-SP) Infused with Ang II
Vascular Disease Prevention (Discontinued) Editorial (Thematic Issue: G-protein Coupled Receptors in Vascular Biology: Implication in Health and Disease)
Current Vascular Pharmacology Nosocomial Infections and Antimicrobial Treatment in Coiled Patients with Aneurysmal Subarachnoid Hemorrhage
Current Drug Targets Regulation of Inflammation and Myocardial Fibrosis in Experimental Autoimmune Myocarditis
Inflammation & Allergy - Drug Targets (Discontinued) Current Pharmacological Treatment of Nonalcoholic Fatty Liver
Current Medicinal Chemistry Sonic Hedgehog Signaling Activation Promotes Cardioprotective Strategies
Current Signal Transduction Therapy Formulation and In Vitro Evaluation of Solid Lipid Microparticles of Candesartan Cilexetil Floating Tablets
Drug Delivery Letters Subject Index To Volume 13
Current Medicinal Chemistry Cystatin C, Adipokines and Cardiovascular Risk in HIV Infected Patients
Current HIV Research VEGF in the Muscular Layer of Placental Blood Vessels: Immuno- Expression in Preeclampsia and Intrauterine Growth Restrictrion and its Association with the Antioxidant Status
Cardiovascular & Hematological Agents in Medicinal Chemistry Novel Therapeutic Targets for Prevention and Therapy of Sepsis Associated Acute Kidney Injury
Current Drug Targets